CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis - PubMed (original) (raw)
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin-Zhi Qian et al. Nature. 2011.
Abstract
Macrophages, which are abundant in the tumour microenvironment, enhance malignancy. At metastatic sites, a distinct population of metastasis-associated macrophages promotes the extravasation, seeding and persistent growth of tumour cells. Here we define the origin of these macrophages by showing that Gr1-positive inflammatory monocytes are preferentially recruited to pulmonary metastases but not to primary mammary tumours in mice. This process also occurs for human inflammatory monocytes in pulmonary metastases of human breast cancer cells. The recruitment of these inflammatory monocytes, which express CCR2 (the receptor for chemokine CCL2), as well as the subsequent recruitment of metastasis-associated macrophages and their interaction with metastasizing tumour cells, is dependent on CCL2 synthesized by both the tumour and the stroma. Inhibition of CCL2-CCR2 signalling blocks the recruitment of inflammatory monocytes, inhibits metastasis in vivo and prolongs the survival of tumour-bearing mice. Depletion of tumour-cell-derived CCL2 also inhibits metastatic seeding. Inflammatory monocytes promote the extravasation of tumour cells in a process that requires monocyte-derived vascular endothelial growth factor. CCL2 expression and macrophage infiltration are correlated with poor prognosis and metastatic disease in human breast cancer. Our data provide the mechanistic link between these two clinical associations and indicate new therapeutic targets for treating metastatic breast cancer.
©2011 Macmillan Publishers Limited. All rights reserved
Figures
Figure 1
Pulmonary metastases preferentially recruit inflammatory monocytes through CCL2. a, Schematic for monocyte adoptive transfer into PyMT tumor mice with pulmonary metastases. b, Ratio of IM versus RM in different tissues of recipient mice bearing PyMT tumors and metastases. n=6, p<0.0001. c, Ratio of IM versus RM in control lung and lungs with i.v. injected Met-1 cells 7 hours before. n=4, p=0.0039. d, Relative donor IMs recruited in lungs challenged with Met-1 cells for 7 hours with control or anti-mouse CCL2 antibody treatment. n=3, p=0.045. e, Ratio of adoptively transferred CD14+CD16− and CD14loCD16+ human monocytes recruited into normal mice (open bars) and mice challenged with LM2 cells (solid bars) for 7 hours, n=5, p=0.0163. b-e, All bar = mean + s.e.m f, Number of adoptively transferred human CD14+CD16− monocytes that migrated into different tissues of mice challenged with LM2 cells via i.v. injection with control or anti-mouse CCL2 Ab treatment n=5, p=0.016, each line connects data from same donor.
Figure 2
CCL2-recruited monocytes promote metastatic seeding. a, Representative H&E stained sections showing Met-1 metastasis with Ab treatment. Bar=1 mm. b, Met-1 metastasis (Mets) burden with different Ab treatment. n=6, p=0.006. c and d, Representative snapshots of 3D reconstructed confocal images of tumor cells (blue) and macrophages (green) in lung vasculature (red) 24 hours after tumor cell tail vein injection in mice treated with control (c) or anti-mouse CCL2 Ab (d). Bar = 20 um. e, Number of macrophage-tumor cell interactions in mice with Ab treatment. f, Tumor cell extravasation in mice with different Ab treatment. (e, p= 0.0066 and f, p=0.00163 are based upon 3D images of 15-20 tumor clusters per mouse, n=3 mice/group.) g, Number of transmigrated Met-1 cells in presence of RMs or IMs. n=5, p<0.0001. h, Number of transmigrated Met-1 cells in presence of IMs with different Ab. n=3, p=0.0204. All bars shown are mean + s.e.m.
Figure 3
Tumor cell and host CCL2 promote metastatic seeding. a, Number of spontaneous pulmonary metastases from orthotopic MDA-MB-231 tumors with total CCL2 blockade or control treatment. Bar equals mean, n= 8/group, p<0.001. b, Mets burden of i.v. injected 4173 cells with different Ab treatment. n=6, p=2.14E-05. Bar equals mean + s.e.m. c, Representative fluorescent micrograph of transmigrated human 4173 cells pre-stained with cell tracker dye in the presence of different monocyte populations. Bar equals 20 um. d, Number of transmigrated 4173 cells in presence of IMs or RMs. Bar equals mean + s.e.m. of 3 experiments with duplicates. e, Relative number of transmigrated 4173 cells in presence of IMs with control, anti-human or anti-mouse CCL2 Ab normalized to average of control Ab which is arbitrarily set to 100. Bar represents mean + s.e.m. of 5 experiments with duplicates. One way anova with Bonferroni’s multiple comparison test, **p<0.01, ***p<0.001. f and g, CCL2 blockade starting from 2 days after MDA-MB-231 cells i.v. injection significantly reduces Mets burden as measured by realtime PCR of human Alu repeats normalized to mouse β actin on day 22 (f, n=10, ***p<0.001) and prolongs survival (g, n=10, p<0.001).
Figure 4
Monocyte-specific ablation of VEGF blocks pulmonary seeding. a, PCR of VEGF exon3 of BMMs of VEGFflox/flox mice with or without Csf1r-Mer-iCre-Mer transgene treated with 4-hydroxytamoxifen. Wild type (WT) and knockout (KO) bands are indicated. b and c, Number of trans-endothelial migrated Met-1 cells without BMM (b) and albumin permeability of endothelial monolayer (c), with WT or VEGF knockout BMMs. n=3 with duplicates. **p<0.01 with ANOVA. d, Relative VEGF exon 3 copy number in leukocytes from the peripheral blood of tamoxifen treated VEGFflox/flox;Csf1r-Mer-iCre-Mer and VEGFflox/flox mice. e, Met-1 Mets burden in VEGFflox/flox mice with or without Cre with same tamoxifen treatment. n=6, p=0.0004. f, Met-1 Mets burden in VEGFflox/flox;Csf1r-Mer-iCre-Mer mice with tamoxifen treatment with or without IM co-injection. n=6, p<0.0001. All data are mean+s.e.m.
Similar articles
- Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis.
Bonapace L, Coissieux MM, Wyckoff J, Mertz KD, Varga Z, Junt T, Bentires-Alj M. Bonapace L, et al. Nature. 2014 Nov 6;515(7525):130-3. doi: 10.1038/nature13862. Epub 2014 Oct 22. Nature. 2014. PMID: 25337873 - Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H. Li X, et al. Gut. 2017 Jan;66(1):157-167. doi: 10.1136/gutjnl-2015-310514. Epub 2015 Oct 9. Gut. 2017. PMID: 26452628 - Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei L, Ren X, Yu H, Zhan Y. Fei L, et al. Front Immunol. 2021 Nov 3;12:771210. doi: 10.3389/fimmu.2021.771210. eCollection 2021. Front Immunol. 2021. PMID: 34804061 Free PMC article. Review. - The molecular structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in skeletal biology and diseases.
Zhu S, Liu M, Bennett S, Wang Z, Pfleger KDG, Xu J. Zhu S, et al. J Cell Physiol. 2021 Oct;236(10):7211-7222. doi: 10.1002/jcp.30375. Epub 2021 Mar 30. J Cell Physiol. 2021. PMID: 33782965 Review.
Cited by
- Metabolomic Alteration in Adipose Monocyte Chemotactic Protein-1 Deficient Mice Fed a High-Fat Diet.
Yan L, Rust BM, Sundaram S, Nielsen FH. Yan L, et al. Nutr Metab Insights. 2024 Sep 28;17:11786388241280859. doi: 10.1177/11786388241280859. eCollection 2024. Nutr Metab Insights. 2024. PMID: 39372559 Free PMC article. - Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment.
Li X, Chen T, Li X, Zhang H, Li Y, Zhang S, Luo S, Zheng T. Li X, et al. Exp Hematol Oncol. 2024 Sep 30;13(1):96. doi: 10.1186/s40164-024-00564-w. Exp Hematol Oncol. 2024. PMID: 39350256 Free PMC article. Review. - HSP90 promotes tumor associated macrophage differentiation during triple-negative breast cancer progression.
Hong L, Tanaka M, Yasui M, Hara-Chikuma M. Hong L, et al. Sci Rep. 2024 Sep 29;14(1):22541. doi: 10.1038/s41598-024-73394-9. Sci Rep. 2024. PMID: 39341960 Free PMC article. - Pre-metastatic niche: formation, characteristics and therapeutic implication.
Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q, Yuan W, Gu X, Hu J, Yang S. Wang Y, et al. Signal Transduct Target Ther. 2024 Sep 25;9(1):236. doi: 10.1038/s41392-024-01937-7. Signal Transduct Target Ther. 2024. PMID: 39317708 Free PMC article. Review. - Metabolic reprogramming of hypoxic tumor-associated macrophages through CSF-1R targeting favors treatment efficiency in colorectal cancers.
Gharzeddine K, Gonzalez Prieto C, Malier M, Hennot C, Grespan R, Yamaryo-Botté Y, Botté CY, Thomas F, Laverriere MH, Girard E, Roth G, Millet A. Gharzeddine K, et al. J Immunother Cancer. 2024 Sep 24;12(9):e009602. doi: 10.1136/jitc-2024-009602. J Immunother Cancer. 2024. PMID: 39317456 Free PMC article.
References
- Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with Image. J. Biophotonics International. 2004;11:36–42.
Publication types
MeSH terms
Substances
Grants and funding
- P01 CA100324/CA/NCI NIH HHS/United States
- G1002033/MRC_/Medical Research Council/United Kingdom
- R01 CA131270-05/CA/NCI NIH HHS/United States
- P01 CA100324-10/CA/NCI NIH HHS/United States
- P30 CA013330/CA/NCI NIH HHS/United States
- R01 CA131270/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous